Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Bausch + Lomb Releases 2025 Sustainability Impact Report

Sustainability Report Confirms Long-Term ESG Goals

By The Northwire Desk — AI Analysis Apr 22, 2026 · 07:15 BLCO · 21.98 BAUSCH + LOMB CORPORATION
Executive Summary
  • The most recent release (April 22, 2026) is a 2025 Sustainability Impact Report detailing "The Broader Perspective" framework.
  • Key commitments include Net Zero greenhouse gas emissions by 2050 and specific waste reduction targets like 10% power demand decrease at the Rochester site.
  • The report highlights progress in packaging weight reduction for contact lenses and digital transitions to reduce paper waste.
  • Previous news (April 8, April 7) confirms FDA clearance for Bi-Blade+ vitrectomy cutter and European launch of enVista Envy IOLs.
  • Financial context from February 2026 earnings shows revenue growth ($5.1B FY25) but widened GAAP net loss ($360M).
  • Refinancing news (December 2025) indicates a $2.8B term loan extension to 2031 with reduced interest margins.
Material Impact
  • The sustainability report is expected corporate governance activity and does not introduce new financial data or product breakthroughs.
  • It reinforces existing commitments made during the Investor Day (November 2025) regarding ESG metrics but lacks immediate revenue implications.
  • Given the company's focus on operational leverage and margin expansion, this news supports long-term risk management rather than short-term stock price appreciation.
  • The material impact is neutral to slightly positive for reputation but does not alter the fundamental valuation drivers (revenue growth vs. GAAP losses).
  • No new strategic investors or major capital raises are announced in this release; financing remains stable with the December refinancing.
BLCO · Price
Company Overview
  • Bausch + Lomb operates in Vision Care, Surgical, and Pharmaceuticals segments with a focus on eye health solutions.
  • Flagship projects include the enVista platform (premium intraocular lenses) and MIEBO (dry-eye pharmaceutical).
  • The Elios laser system for glaucoma treatment is a key development asset pending US FDA approval for launch in H2 2026.
  • The company recently separated from Bausch Health Companies Inc., aiming to operate as an independent entity with streamlined operations.
  • Revenue growth is driven by the dry-eye portfolio and premium IOLs, though GAAP profitability remains challenged by restructuring and tax provisions.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other